quetiapine-fumarate and Cataract

Clinical observations indicate no cataractogenic potential for quetiapine, in contrast to studies in laboratory animals. This randomized, non-inferiority study compared changes in lens opacity during long-term treatment with quetiapine versus risperidone. Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study. Two ophthalmologists examined each patient 6-monthly for presence of nuclear opalescence (N) and cortical (C) or posterior subcapsular opacification (P), according to the lens opacities classification system II. 1098 patients were randomized to treatment. Mean doses were 386.3 mg/day quetiapine and 3.2 mg/day risperidone. Estimated absolute risk differences in cataractogenic events for quetiapine versus risperidone over 2 years were -0.035 (C), -0.012 (N) and -0.017 (P), with upper margins of confidence intervals within the non-inferiority margin of 10%. In post hoc analysis, risk of any lens opacification event was significantly lower for quetiapine than risperidone (6 and 16 events, respectively; risk difference: -0.058; P = 0.035). Efficacy and other safety assessments were in agreement with known profiles of these medications. Quetiapine was non-inferior to risperidone for changes in lens opacity grade in patients with schizophrenia or schizoaffective disorder, indicating that quetiapine does not have clinically significant cataractogenic potential during long-term treatment.

Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cataract; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

Topics: Antipsychotic Agents; Cataract; Consensus; Dibenzothiazepines; Drug Labeling; Humans; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Prevention; Tobacco Use Disorder; Vision Tests

Topics: Animals; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Monitoring; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Physical Examination; Quetiapine Fumarate

Topics: Adult; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Psychotic Disorders; Quetiapine Fumarate

To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy.. Observational case series.. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis.. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses.. Cataractogenesis secondary to quetiapine is "unlikely" by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.

Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Cataract; Child; Dibenzothiazepines; Drug Monitoring; Female; Guidelines as Topic; Humans; Lens, Crystalline; Male; Middle Aged; Physical Examination; Quetiapine Fumarate; Registries; United States; World Health Organization

Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Cataract; Dibenzothiazepines; Humans; Male; Quetiapine Fumarate; Risk Factors; Schizophrenia

Topics: Adult; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome

Topics: Antipsychotic Agents; Attitude of Health Personnel; Cataract; Dibenzothiazepines; Humans; Ophthalmology; Patient Care Team; Quetiapine Fumarate; Schizophrenia